Engene to present at the jefferies global healthcare conference

Boston & montreal--(business wire)--engene holdings inc. (nasdaq: engn or “engene” or the “company”), a clinical-stage genetic medicines company whose non-viral lead program eg-70 is in a pivotal study for bcg-unresponsive non-muscle invasive bladder cancer (nmibc), today announced that jason hanson, chief executive officer, will present a corporate overview at the jefferies global healthcare conference in new york city, on june 5, 2024, at 12:30 p.m. et. a live webcast of the presentation can.
ENGN Ratings Summary
ENGN Quant Ranking